文献速递头颈外科

局部免疫参数作为头颈部鳞状细胞癌患者接受诱导化疗联合西妥昔单抗治疗的潜在预测标志物

Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.
PubMed 文献 · Head Neck · 2018-12-12

该回顾性研究对45例III-IV期可切除头颈部鳞状细胞癌患者的治疗前活检标本进行免疫组化检测,分析多种免疫细胞密度与临床病理参数、治疗反应及生存的相关性。发现DC-LAMP+成熟树突状细胞和PD-1+淋巴细胞密度与诱导化疗反应显著相关,DC-LAMP+细胞密度还与无进展生存期相关。作者认为这些免疫细胞可能参与诱导化疗联合西妥昔单抗的治疗反应。

要点

  • DC-LAMP+成熟树突状细胞和PD-1+淋巴细胞密度与诱导化疗反应显著相关。
  • DC-LAMP+细胞密度与无进展生存期相关。
  • 其他免疫细胞类型与治疗反应未见显著关联。

核心结论

  • DC-LAMP+成熟树突状细胞和PD-1+细胞可能参与头颈部鳞状细胞癌患者对诱导化疗联合西妥昔单抗的治疗反应。

研究设计与样本

  • 回顾性研究,纳入45例III-IV期可切除头颈部鳞状细胞癌患者,对治疗前石蜡包埋活检标本进行免疫组化检测,分析CD8、FOXP3、CD134、CD137、PD-1、CD20、NKp46、DC-LAMP、CD16、CD68和髓过氧化物酶表达的免疫细胞密度与临床病理参数、治疗反应及生存的相关性。

主要发现

  • 在研究的免疫细胞类型中,仅DC-LAMP+成熟树突状细胞和PD-1+淋巴细胞密度与诱导化疗反应显著相关。
  • DC-LAMP+细胞密度还与无进展生存期相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to determine whether tumor-associated immune cells may predict response to therapy and disease outcome in head and neck squamous cell carcinoma (HNSCC) patients receiving induction chemotherapy and cetuximab. METHODS: Paraffin-embedded pretreatment biopsy samples from 45 patients with stage III-IV resectable HNSCC were investigated retrospectively by immunohistochemistry for density of different immune cell types based on expression of CD8, FOXP3, CD134, CD137, PD-1, CD20, NKp46, dendritic cell lysosomal-associated membrane protein (DC-LAMP), CD16, CD68, and myeloperoxidase. Results were analyzed for possible correlations with clinicopathologic parameters, response to therapy, and survival. RESULTS: Of the immune cell types studied, we found significant association with response to induction chemotherapy only in the case of DC-LAMP+ mature dendritic cells and PD-1+ lymphocytes; density of DC-LAMP+ cells also correlated with progression-free survival. CONCLUSION: DC-LAMP+ mature dendritic cells and PD-1+ cells may be implicated in response to induction chemotherapy and cetuximab in HNSCC patients.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Ladányi A, Kapuvári B, Papp E, et al. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab. Head Neck. 2018. PMID: 30548478. doi:10.1002/hed.25546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。